| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7ddc4774cf5f8a0bda44a780d73c53d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-335 |
| filingDate |
2011-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7997126de7f7e531e4bb5a8f94f1d3a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cf9a4f0086aa1acc86fd0ce677587e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_102f323829ea35e610998ca58d10f686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9de0db50518c4aa3e2520313d1e4d513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17a13e8d138e16c7d0b3da6595f7e375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b00b1779e111b53c9e406bbca0a5f1f |
| publicationDate |
2013-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20130030606-A |
| titleOfInvention |
Pharmaceutical composition with improved stability, comprising corticosteroids, antihistamines and β-cyclodextrins |
| abstract |
The present invention relates to corticosteroids or pharmaceutically acceptable salts; Antihistamines selected from the group consisting of olopatadine, azelastine and pharmaceutically acceptable salts thereof; And relates to a pharmaceutical composition comprising β-cyclodextrin, and a method for preparing the same, the pharmaceutical composition according to the present invention is inhibited insoluble foreign matter production and the solubility of the antihistamine is increased, so it is stable without precipitation of the active ingredient even in long-term storage, It can be usefully used as a nasal spray solution for the treatment of allergic inflammation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019076798-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11642309-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3725298-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020212380-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020536972-A |
| priorityDate |
2011-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |